Bortezomib interactions with chemotherapy agents in acute leukemia in vitro-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

Published:2005-11-15 Issue:1 Volume:58 Page:13-23
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Horton Terzah M.,Gannavarapu Anurhadha,Blaney Susan M.,D’Argenio David Z.,Plon Sharon E.,Berg Stacey L.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-005-0135-z.pdf

Reference57 articles.

1. SEER Cancer Statistic Review, 1973–1999 Bethesda, MD: National Cancer Institute, 2000;467–482

2. Hochstrasser M (1995) Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 7:215–223

3. Spataro V, Norbury C, Harris AL (1998) The ubiquitin-proteasome pathway in cancer. Br J Cancer 77:448–455

4. Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79:13–21

5. Karin M, Cao Y, Greten FR et al (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301–310

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigates the genetic types of acute lymphoblastic leukemia in full remission Indonesian patients: a cross-sectional analysis;American Journal of BioMedicine;2024-04-11

2. Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial;Cancers;2024-04-09

3. Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels;Cureus;2023-12-02

4. Therapeutic approaches for HTLV-1-associated adult T-cell leukemia/lymphoma: a comprehensive review;Medical Oncology;2023-09-09

5. Relapsed/Refractory T- Acute Lymphoblastic Leukemia — Current Options and Future Directions;Indian Journal of Pediatrics;2023-08-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3